Koninklijke Philips Valuation
Is PHIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PHIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PHIA (€24.2) is trading below our estimate of fair value (€60.98)
Significantly Below Fair Value: PHIA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PHIA?
Key metric: As PHIA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is PHIA's PS Ratio? | |
|---|---|
| PS Ratio | 1.3x |
| Sales | €18.04b |
| Market Cap | €22.95b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 18.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PHIA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2x | ||
SHL Siemens Healthineers | 2.5x | 5.8% | €55.0b |
AFX Carl Zeiss Meditec | 2.5x | 7.9% | €5.2b |
DRW3 Drägerwerk KGaA | 0.2x | 4.2% | €792.7m |
EUZ Eckert & Ziegler | 2.9x | 6.3% | €795.9m |
PHIA Koninklijke Philips | 1.3x | 4.6% | €22.9b |
Price-To-Sales vs Peers: PHIA is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (2x).
Price to Sales Ratio vs Industry
How does PHIA's PS Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Sales vs Industry: PHIA is good value based on its Price-To-Sales Ratio (1.3x) compared to the European Medical Equipment industry average (3.4x).
Price to Sales Ratio vs Fair Ratio
What is PHIA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.3x |
| Fair PS Ratio | 2.2x |
Price-To-Sales vs Fair Ratio: PHIA is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Ship Healthcare Holdings
JP¥196.5b
Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.
5EZ
JP¥12.40
7D
-3.1%
1Y
-4.6%
Sensus Healthcare
US$125.2m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$7.25
7D
16.0%
1Y
272.6%
CVS Health
US$66.9b
Provides health solutions in the United States.
CVS
US$53.25
7D
2.4%
1Y
-14.7%